Fedratinib Earns Priority Review Status for Myelofibrosis From FDA - https://t.co/aKeLjhpYhA Managed Markets Network https://t.co/nyLOUr6y93
— IDRO (@IDROOhio) March 8, 2019
from Twitter https://twitter.com/IDROOhio
March 08, 2019 at 12:12AM
Friday, March 8, 2019
Fedratinib Earns Priority Review Status for Myelofibrosis From FDA - https://t.co/aKeLjhpYhA Managed Markets Network https://t.co/nyLOUr6y93
from Twitter https://twitter.com/IDROOhio
March 08, 2019 at 12:12AM
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment